Trial Profile
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary)
- Indications Anaplastic large cell lymphoma; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 13 Mar 2023 Status changed from active, no longer recruiting to completed.
- 18 Jan 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 26 Jul 2020 Planned End Date changed from 1 Jan 2020 to 1 Jul 2021.